Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -0.04 is 93% above its 4-year average of -0.53, near the high end of its 4-year range (-1.25–-0.04).
68.97% above its 12-month average of -0.13.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): 0.05.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 15 comparable quarters.
EARNINGS PER SHARE (EPS)
-0.04
EARNINGS PER SHARE (EPS) AVG TTM
-0.13
EARNINGS PER SHARE (EPS) AVG 3Y
-0.35
EARNINGS PER SHARE (EPS) AVG 5Y
-0.53
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
+68.97%
CURRENT VS 3Y AVG
+88.71%
CURRENT VS 5Y AVG
+92.50%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Clover Health Investments, Corp.
Market Cap
$2.43B
Earnings Per Share (EPS)
-0.04
TTM Avg
-0.13
3Y Avg
-0.35
5Y Avg
-0.53
Market Cap
$2.34B
Earnings Per Share (EPS)
0.70
TTM Avg
0.73
3Y Avg
0.23
5Y Avg
-0.12
Market Cap
$2.51B
Earnings Per Share (EPS)
-1.04
TTM Avg
-1.56
3Y Avg
-1.52
5Y Avg
-1.27
Market Cap
$2.64B
Earnings Per Share (EPS)
-0.86
TTM Avg
-2.70
3Y Avg
-2.81
5Y Avg
-3.40
Market Cap
$2.64B
Earnings Per Share (EPS)
N/A
TTM Avg
-0.45
3Y Avg
-0.45
5Y Avg
-0.45
Market Cap
$2.17B
Earnings Per Share (EPS)
-4.36
TTM Avg
-3.17
3Y Avg
-2.92
5Y Avg
-2.56
Market Cap
$2.69B
Earnings Per Share (EPS)
-12.45
TTM Avg
-4.69
3Y Avg
-1.64
5Y Avg
-2.01
Market Cap
$2.69B
Earnings Per Share (EPS)
1.26
TTM Avg
1.10
3Y Avg
0.11
5Y Avg
-0.77
Market Cap
$2.11B
Earnings Per Share (EPS)
5.70
TTM Avg
4.76
3Y Avg
4.08
5Y Avg
3.55
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Clover Health Investments, Corp. (CLOV) | $2.43B | -0.04 | -0.13 | -0.35 | -0.53 |
| ADMA Biologics, Inc. (ADMA)vs › | $2.34B | 0.70 | 0.73 | 0.23 | -0.12 |
| Recursion Pharmaceuticals, Inc. (RXRX)vs › | $2.51B | -1.04 | -1.56 | -1.52 | -1.27 |
| Beam Therapeutics Inc. (BEAM)vs › | $2.64B | -0.86 | -2.70 | -2.81 | -3.40 |
| Alamar Biosciences, Inc. (ALMR)vs › | $2.64B | N/A | -0.45 | -0.45 | -0.45 |
| Celldex Therapeutics, Inc. (CLDX)vs › | $2.17B | -4.36 | -3.17 | -2.92 | -2.56 |
| Acadia Healthcare Company, Inc. (ACHC)vs › | $2.69B | -12.45 | -4.69 | -1.64 | -2.01 |
| Aveanna Healthcare Holdings Inc. (AVAH)vs › | $2.69B | 1.26 | 1.10 | 0.11 | -0.77 |
| Addus HomeCare Corporation (ADUS)vs › | $2.11B | 5.70 | 4.76 | 4.08 | 3.55 |
| Alvotech (ALVO)vs › | $2.07B | -0.63 | -0.39 | -1.45 | -2.42 |
Trailing EPS (TTM)
$-0.04
Forward EPS (Est.)
$0.06
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -0.17 |
| 2024-12-31 | -0.09 |
| 2023-12-31 | -0.45 |
| 2022-12-31 | -0.71 |
| 2021-12-31 | -1.25 |
| 2019-12-31 | -0.90 |
| 2018-12-31 | -4.81 |
